NO20051066L - Arylsubstituerte benzimidazoler og deres anvendelse som natriumkanalblokkere - Google Patents

Arylsubstituerte benzimidazoler og deres anvendelse som natriumkanalblokkere

Info

Publication number
NO20051066L
NO20051066L NO20051066A NO20051066A NO20051066L NO 20051066 L NO20051066 L NO 20051066L NO 20051066 A NO20051066 A NO 20051066A NO 20051066 A NO20051066 A NO 20051066A NO 20051066 L NO20051066 L NO 20051066L
Authority
NO
Norway
Prior art keywords
aryl
prevention
treatment
substituted benzimidazoles
sodium channel
Prior art date
Application number
NO20051066A
Other languages
English (en)
Inventor
Qun Sun
Donald J Kyle
Xiaoming Zhou
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20051066L publication Critical patent/NO20051066L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Denne oppfinnelsen vedrører arylsub- stituerte benzimidazoler med formel (I), (Rio)n y (I) Ri eller et farmasøytisk akseptabelt salt, prolegemiddel eller solvat derav der Ri, R2, Rio og n er definert i beskrivelsen. Oppfinnelsen er også rettet mot anvendelsen av forbindelser med fonnel (I) dl behandling av nevronal skade som følge av global og fokal iskemi, forbehandlingen eller forbyggingen av nevrodegenerative tilstander, slik som amyotrofisk lateral sklerose (ALS), og for behandlingen, forebyggingen eller lindringen av både akutt og kronisk smerte, som antitiimitusmidler som antikrampefremkallende midler og som antiraaniske depresjonsmidler, som lokalbedøvende midler, som antiarytmi- midler og for behandlingen eller forebygging av diabetisk nevropati.
NO20051066A 2002-07-31 2005-02-25 Arylsubstituerte benzimidazoler og deres anvendelse som natriumkanalblokkere NO20051066L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39945802P 2002-07-31 2002-07-31
PCT/US2003/023828 WO2004011439A2 (en) 2002-07-31 2003-07-31 Aryl substituted benzimidazoles and their use as sodium channel blockers

Publications (1)

Publication Number Publication Date
NO20051066L true NO20051066L (no) 2005-02-25

Family

ID=31188586

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051066A NO20051066L (no) 2002-07-31 2005-02-25 Arylsubstituerte benzimidazoler og deres anvendelse som natriumkanalblokkere

Country Status (13)

Country Link
US (1) US7022714B2 (no)
EP (1) EP1532119A2 (no)
JP (1) JP2006504660A (no)
KR (1) KR20050026031A (no)
CN (1) CN1671672A (no)
AU (1) AU2003257033A1 (no)
BR (1) BR0313352A (no)
CA (1) CA2492305A1 (no)
EA (1) EA200500289A1 (no)
IL (1) IL166366A0 (no)
MX (1) MXPA05000812A (no)
NO (1) NO20051066L (no)
WO (1) WO2004011439A2 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
AU2006209117B2 (en) * 2005-01-28 2009-12-10 Daewoong Pharmaceutical Co., Ltd. Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
CN101490037B (zh) * 2006-07-11 2013-06-12 大熊制药株式会社 联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物
EP2582666B1 (en) * 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
CN103180308B (zh) 2010-09-28 2015-04-08 大熊制药株式会社 制备苯并咪唑衍生物的方法
AU2011311238A1 (en) 2010-10-05 2013-04-04 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
JP2014500303A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としての置換ピリジン
AU2012300567B2 (en) 2011-09-02 2016-03-10 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
AU2012324010A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
CA2861439C (en) * 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
AU2014224310B2 (en) 2013-03-04 2017-02-09 Purdue Pharma L.P. Pyrimidine carboxamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
CA2922567A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
WO2015112801A1 (en) 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
AU2015217185B2 (en) 2014-02-12 2018-04-05 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US9975854B2 (en) 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
US20230212121A1 (en) * 2020-05-29 2023-07-06 Daegu-Gyeongbuk Medical Innovation Foundation Sulfonamide derivative and pharmaceutical composition comprising same as active ingredient for preventing or treating mental illness

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
EP0922028A1 (en) 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
CA2322163A1 (en) 1998-02-25 1999-09-02 John Mckew Inhibitors of phospholipase a2
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
ES2345921T3 (es) * 1999-03-26 2010-10-06 Euro-Celtique S.A. Pirazoles, imidazoles, oxazoles, tiazoles y pirroles sustituidos con arilo y su uso.
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2400778C (en) * 2000-03-24 2011-05-03 Purdue Pharma L.P. Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
NZ521870A (en) * 2000-03-31 2004-08-27 Euro Celtique S Aminopyridines and their use as anticonvulsants and sodium channel blockers
RU2269523C2 (ru) 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
GB0017256D0 (en) * 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
CA2453633A1 (en) * 2001-07-16 2003-01-30 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) * 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
EA200401120A1 (ru) * 2002-03-13 2005-02-24 Еуро-Селтик С. А. Арилзамещенные пиримидины и их применение

Also Published As

Publication number Publication date
WO2004011439A3 (en) 2004-04-01
CN1671672A (zh) 2005-09-21
IL166366A0 (en) 2006-01-16
US7022714B2 (en) 2006-04-04
AU2003257033A1 (en) 2004-02-16
WO2004011439A2 (en) 2004-02-05
EA200500289A1 (ru) 2005-06-30
CA2492305A1 (en) 2004-02-05
US20040132777A1 (en) 2004-07-08
MXPA05000812A (es) 2005-04-19
KR20050026031A (ko) 2005-03-14
EP1532119A2 (en) 2005-05-25
JP2006504660A (ja) 2006-02-09
BR0313352A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
WO2004011439A3 (en) Aryl substituted benzimidazoles and their use as sodium channel blockers
MXPA04002171A (es) Piridicarboxamidas aril sustituidas y su uso como bloqueadores del canal de sodio.
MXPA05000813A (es) Compuestos hidrantoina aril sustituidos y su uso como bloqueadores del canal de sodio.
MXPA02009619A (es) Aminopiridinas y su uso como anticonvulsivos y bloqueadores del canal de sodio.
NO20044311L (no) Aryl-substituerte pyrimidiner og anvendelsen derav
YU68701A (sh) Aril supstituisani pirazoli, imidazoli, oksazoli, tiazoli i piroli i njihova upotreba
ATE440603T1 (de) 8-hydroxychinolinderivate
MXPA04002172A (es) Derivados de piridina 2-(4-fenoxi)heterociclicos substituidos, compuestos relacionados como bloqueadores de canal de sodio para tratamiento de dano neurologico y neurodegenerativo.
WO2001072714A3 (en) Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
CR6774A (es) Sustitutos arilicos de piridinas, pirimidinas, pirazinas, triazinas y el uso de estos
PA8557001A1 (es) Nuevos derivados de pirrolidina
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
ATE297203T1 (de) Antithrombotische mitteln
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
ATE306261T1 (de) Antithrombosemittel
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
BR0305708A (pt) Derivados de benzimidazol para o tratamento de disfunção sexual
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
UY28486A1 (es) Compuestos quimicos
ATE308540T1 (de) Antithrombosemittel
SE0002739D0 (sv) New use